会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • MUTANTS OF O<6>-ALKYLGUANINE-DNA ALKYLTRANSFERASE
    • O 6 - 烷基鸟嘌呤-DNA烷基转移酶的突变体
    • WO2005085431A2
    • 2005-09-15
    • PCT/EP2005050899
    • 2005-03-01
    • EPFL ECOLE POLYTECHNIQUE FEDERALE LAUSANNEBARNIKOV JANCHIDLEY CHRISTOPHERGRONEMEYER THOMASHEINIS CHRISTIANJACCARD HUGHESJOHNSSON KAIJUILLERAT ALEXANDREKEPPLER ANTJE
    • BARNIKOV JANCHIDLEY CHRISTOPHERGRONEMEYER THOMASHEINIS CHRISTIANJACCARD HUGHESJOHNSSON KAIJUILLERAT ALEXANDREKEPPLER ANTJE
    • C12N9/10C12N15/62G01N33/535
    • C12N9/10C07K2319/00C12N9/1007
    • The invention relates to AGT mutants showing, when compared to the wild type human AGT, two or more advantageous properties selected from (a) reduced DNA interaction; (b) localisation of the expressed protein in eukaryotic cells that is no longer restricted to the nucleus; (c) improved expression yield as soluble protein and improved stability in various hosts; (d) improved stability under oxidising conditions; (e) improved stability within cells after reaction with a substrate; (f) improved stability outside cells before and after reaction with a substrate; (g) improved in vitro solubility; (h) improved reactivity against 0 -alkylguanine substrates; (1) reduced reactivity against DNA-based substrates; and (j) reduced reactivity against N -substituted 0 -alkylguanine substrates. Such AGT mutants with the mentioned improved properties are mutants wherein between 1 and 25 amino acids of the wild type human AGT are substituted by other amino acids, and optionally I to 5 amino acids out of the continuous chain at one, two or three positions are deleted or added and/or 1 to 4 amino acids at the N-terminus or 1 to 40 amino acids at the C-terminus are deleted. The invention further relates to a method for detecting and/or manipulating a protein of interest wherein the protein of interest is incorporated into a fusion protein with the AGT mutants of the invention. Another object of the invention are AGT fusion proteins comprising such AGT mutants and the protein of interest.
    • 本发明涉及AGT突变体,当与野生型人AGT比较时,显示选自以下的两种或更多种有利特性:(a)减少的DNA相互作用; (b)表达蛋白在不再限于细胞核的真核细胞中定位; (c)作为可溶性蛋白的提高的表达产量和改善的各种宿主的稳定性; (d)在氧化条件下改善稳定性; (e)与基质反应后细胞内稳定性提高; (f)在与基质反应之前和之后改善细胞外的稳定性; (g)体外溶解度提高; (h)提高了对0-6-烷基鸟嘌呤底物的反应性; (1)对DNA基底物的反应性降低; 和(j)对N 9 - 取代的0-6-烷基鸟嘌呤底物的反应性降低。 具有提到的改进性质的这种AGT突变体是这样的突变体,其中野生型人AGT的1至25个氨基酸被其他氨基酸取代,并且任选地在连续链之外的1至5个氨基酸的一个,两个或三个位置是 缺失或添加,和/或N端的1至4个氨基酸或C端的1至40个氨基酸缺失。 本发明进一步涉及用于检测和/或操纵感兴趣的蛋白质的方法,其中感兴趣的蛋白质与本发明的AGT突变体并入融合蛋白质中。 本发明的另一个目的是包含这种AGT突变体和感兴趣的蛋白质的AGT融合蛋白。
    • 3. 发明申请
    • MUTANTS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
    • O6-ALKYLGUANINE-DNA烷基转移酶的突变体
    • WO2005085431A9
    • 2006-10-12
    • PCT/EP2005050899
    • 2005-03-01
    • EPFL ECOLE POLYTECHNIQUE FEDERALE LAUSANNEBARNIKOV JANCHIDLEY CHRISTOPHERGRONEMEYER THOMASHEINIS CHRISTIANJACCARD HUGHESJOHNSSON KAIJUILLERAT ALEXANDREKEPPLER ANTJE
    • BARNIKOV JANCHIDLEY CHRISTOPHERGRONEMEYER THOMASHEINIS CHRISTIANJACCARD HUGHESJOHNSSON KAIJUILLERAT ALEXANDREKEPPLER ANTJE
    • C12N9/10
    • C12N9/10C07K2319/00C12N9/1007
    • The invention relates to AGT mutants showing, when compared to the wild type human AGT, two or more advantageous properties selected from (a) reduced DNA interaction; (b) localisation of the expressed protein in eukaryotic cells that is no longer restricted to the nucleus; (c) improved expression yield as soluble protein and improved stability in various hosts; (d) improved stability under oxidising conditions; (e) improved stability within cells after reaction with a substrate; (f) improved stability outside cells before and after reaction with a substrate; (g) improved in vitro solubility; (h) improved reactivity against 0 6 -alkylguanine substrates; (1) reduced reactivity against DNA-based substrates; and (j) reduced reactivity against N 9 -substituted 0 6 -alkylguanine substrates. Such AGT mutants with the mentioned improved properties are mutants wherein between 1 and 25 amino acids of the wild type human AGT are substituted by other amino acids, and optionally I to 5 amino acids out of the continuous chain at one, two or three positions are deleted or added and/or 1 to 4 amino acids at the N-terminus or 1 to 40 amino acids at the C-terminus are deleted. The invention further relates to a method for detecting and/or manipulating a protein of interest wherein the protein of interest is incorporated into a fusion protein with the AGT mutants of the invention. Another object of the invention are AGT fusion proteins comprising such AGT mutants and the protein of interest.
    • 本发明涉及AGT突变体,当与野生型人AGT相比时,显示出选自(a)减少的DNA相互作用的两种或更多种有利性质; (b)表达的蛋白质在不再限于细胞核的真核细胞中的定位; (c)提高作为可溶性蛋白质的表达产率和改善各种宿主的稳定性; (d)改善氧化条件下的稳定性; (e)在与底物反应后改善细胞内的稳定性; (f)在与底物反应之前和之后提高细胞外的稳定性; (g)提高体外溶解度; (h)改善对0-6个 - 烷基鸟嘌呤底物的反应性; (1)降低对DNA基底层的反应性; 和(j)对N 9 - 取代的0-6-烷基鸟嘌呤底物的反应性降低。 具有上述改进性质的这种AGT突变体是突变体,其中野生型人AGT的1至25个氨基酸被其它氨基酸取代,并且在一个,两个或三个位置上,连续链中任选地I至5个氨基酸是 在N-末端缺失或添加和/或1至4个氨基酸或C末端的1至40个氨基酸被缺失。 本发明还涉及用于检测和/或操纵感兴趣的蛋白质的方法,其中将目的蛋白质与本发明的AGT突变体掺入融合蛋白中。 本发明的另一个目的是包含这种AGT突变体和目的蛋白质的AGT融合蛋白。